Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Short term Debt (2024 - 2025)

Humacyte has reported Short term Debt over the past 2 years, most recently at $3.1 million for Q3 2025.

  • Quarterly results put Short term Debt at $3.1 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $3.1 million (changed N/A YoY), and the annual figure for FY2024 was $885000.0, changed.
  • Short term Debt for Q3 2025 was $3.1 million at Humacyte, up from $2.1 million in the prior quarter.
  • Over the last five years, Short term Debt for HUMA hit a ceiling of $3.1 million in Q3 2025 and a floor of $885000.0 in Q4 2024.